P591: PRELIMINARY RESULTS OF A PHASE I STUDY OF CLIFUTINIB, A HIGHLY SELECTIVE, POTENT ORAL FLT-3 INHIBITOR, IN PATINETS WITH FLT3-MUTATED RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-06-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000845252.68424.50 |
| _version_ | 1797287912447934464 |
|---|---|
| author | W. Yu X. Wei Z. Ge Y. Li Z. Jiang L. Yang L. Lin Y. Yao X. Deng X. Du Y. Li T. Chen X. Feng J. Zhou M. Hou R. Fu J. Lan X. Hu S. Huang J. Wang X. Du H. Yang H. Yang H. Wang L. Zheng Z. Wang B. Liu N. Kang Y. Zhuang Y. Zhang J. Jin |
| author_facet | W. Yu X. Wei Z. Ge Y. Li Z. Jiang L. Yang L. Lin Y. Yao X. Deng X. Du Y. Li T. Chen X. Feng J. Zhou M. Hou R. Fu J. Lan X. Hu S. Huang J. Wang X. Du H. Yang H. Yang H. Wang L. Zheng Z. Wang B. Liu N. Kang Y. Zhuang Y. Zhang J. Jin |
| author_sort | W. Yu |
| collection | DOAJ |
| first_indexed | 2024-03-07T18:41:42Z |
| format | Article |
| id | doaj.art-88ae46856040486896cb51bcdeb03ffc |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T18:41:42Z |
| publishDate | 2022-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-88ae46856040486896cb51bcdeb03ffc2024-03-02T03:51:51ZengWileyHemaSphere2572-92412022-06-01649049110.1097/01.HS9.0000845252.68424.50202206003-00490P591: PRELIMINARY RESULTS OF A PHASE I STUDY OF CLIFUTINIB, A HIGHLY SELECTIVE, POTENT ORAL FLT-3 INHIBITOR, IN PATINETS WITH FLT3-MUTATED RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIAW. Yu0X. Wei1Z. Ge2Y. Li3Z. Jiang4L. Yang5L. Lin6Y. Yao7X. Deng8X. Du9Y. Li10T. Chen11X. Feng12J. Zhou13M. Hou14R. Fu15J. Lan16X. Hu17S. Huang18J. Wang19X. Du20H. Yang21H. Yang22H. Wang23L. Zheng24Z. Wang25B. Liu26N. Kang27Y. Zhuang28Y. Zhang29J. Jin301 The First Affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou2 Henan Cancer Hospital, Zhengzhou3 Zhongda Hospital, Southeast University, Nanjing4 Zhujiang Hospital of Southern Medical University, Guangzhou5 The First Affiliated Hospital of Zhengzhou University, Zhengzhou6 The Second Hospital of Shanxi Medical University, Taiyuan7 Hainan General Hospital, Haikou8 Baoji Central Hospital, Baoji9 Weihai Municipal Hospital, Weihai10 Guangdong General Hospital11 Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou12 Huashan Hospital, Shanghai13 The Affiliated Hospital of Qingdao University, Qingdao14 Wuhan Tongji Hospital, Wuhan15 Qilu Hospital of Shandong University, Jinan16 Tianjin Medical University General Hospital, Tianjin17 Zhejiang Provincial People’s Hospital, Hangzhou18 Beida Medical Treatment Luzhong Hospital, Zibo19 Xi’an Gaoxin Hospital, Xian20 Aerospace Center Hospital, Beijing21 The Second People’s Hospital of Shenzhen, Shenzhen22 Shunde Hospital of Southern Medical University, Foshan23 The 1st Affiliated Hospital of He’nan University of Science and Technology, Luoyang1 The First Affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou24 Sunshine Lake Pharma Co., Ltd, Dongguan, China24 Sunshine Lake Pharma Co., Ltd, Dongguan, China24 Sunshine Lake Pharma Co., Ltd, Dongguan, China24 Sunshine Lake Pharma Co., Ltd, Dongguan, China24 Sunshine Lake Pharma Co., Ltd, Dongguan, China24 Sunshine Lake Pharma Co., Ltd, Dongguan, China1 The First Affiliated Hospital of College of Medicine, Zhejiang University, Hangzhouhttp://journals.lww.com/10.1097/01.HS9.0000845252.68424.50 |
| spellingShingle | W. Yu X. Wei Z. Ge Y. Li Z. Jiang L. Yang L. Lin Y. Yao X. Deng X. Du Y. Li T. Chen X. Feng J. Zhou M. Hou R. Fu J. Lan X. Hu S. Huang J. Wang X. Du H. Yang H. Yang H. Wang L. Zheng Z. Wang B. Liu N. Kang Y. Zhuang Y. Zhang J. Jin P591: PRELIMINARY RESULTS OF A PHASE I STUDY OF CLIFUTINIB, A HIGHLY SELECTIVE, POTENT ORAL FLT-3 INHIBITOR, IN PATINETS WITH FLT3-MUTATED RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA HemaSphere |
| title | P591: PRELIMINARY RESULTS OF A PHASE I STUDY OF CLIFUTINIB, A HIGHLY SELECTIVE, POTENT ORAL FLT-3 INHIBITOR, IN PATINETS WITH FLT3-MUTATED RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA |
| title_full | P591: PRELIMINARY RESULTS OF A PHASE I STUDY OF CLIFUTINIB, A HIGHLY SELECTIVE, POTENT ORAL FLT-3 INHIBITOR, IN PATINETS WITH FLT3-MUTATED RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA |
| title_fullStr | P591: PRELIMINARY RESULTS OF A PHASE I STUDY OF CLIFUTINIB, A HIGHLY SELECTIVE, POTENT ORAL FLT-3 INHIBITOR, IN PATINETS WITH FLT3-MUTATED RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA |
| title_full_unstemmed | P591: PRELIMINARY RESULTS OF A PHASE I STUDY OF CLIFUTINIB, A HIGHLY SELECTIVE, POTENT ORAL FLT-3 INHIBITOR, IN PATINETS WITH FLT3-MUTATED RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA |
| title_short | P591: PRELIMINARY RESULTS OF A PHASE I STUDY OF CLIFUTINIB, A HIGHLY SELECTIVE, POTENT ORAL FLT-3 INHIBITOR, IN PATINETS WITH FLT3-MUTATED RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA |
| title_sort | p591 preliminary results of a phase i study of clifutinib a highly selective potent oral flt 3 inhibitor in patinets with flt3 mutated relapsed or refractory acute myeloid leukemia |
| url | http://journals.lww.com/10.1097/01.HS9.0000845252.68424.50 |
| work_keys_str_mv | AT wyu p591preliminaryresultsofaphaseistudyofclifutinibahighlyselectivepotentoralflt3inhibitorinpatinetswithflt3mutatedrelapsedorrefractoryacutemyeloidleukemia AT xwei p591preliminaryresultsofaphaseistudyofclifutinibahighlyselectivepotentoralflt3inhibitorinpatinetswithflt3mutatedrelapsedorrefractoryacutemyeloidleukemia AT zge p591preliminaryresultsofaphaseistudyofclifutinibahighlyselectivepotentoralflt3inhibitorinpatinetswithflt3mutatedrelapsedorrefractoryacutemyeloidleukemia AT yli p591preliminaryresultsofaphaseistudyofclifutinibahighlyselectivepotentoralflt3inhibitorinpatinetswithflt3mutatedrelapsedorrefractoryacutemyeloidleukemia AT zjiang p591preliminaryresultsofaphaseistudyofclifutinibahighlyselectivepotentoralflt3inhibitorinpatinetswithflt3mutatedrelapsedorrefractoryacutemyeloidleukemia AT lyang p591preliminaryresultsofaphaseistudyofclifutinibahighlyselectivepotentoralflt3inhibitorinpatinetswithflt3mutatedrelapsedorrefractoryacutemyeloidleukemia AT llin p591preliminaryresultsofaphaseistudyofclifutinibahighlyselectivepotentoralflt3inhibitorinpatinetswithflt3mutatedrelapsedorrefractoryacutemyeloidleukemia AT yyao p591preliminaryresultsofaphaseistudyofclifutinibahighlyselectivepotentoralflt3inhibitorinpatinetswithflt3mutatedrelapsedorrefractoryacutemyeloidleukemia AT xdeng p591preliminaryresultsofaphaseistudyofclifutinibahighlyselectivepotentoralflt3inhibitorinpatinetswithflt3mutatedrelapsedorrefractoryacutemyeloidleukemia AT xdu p591preliminaryresultsofaphaseistudyofclifutinibahighlyselectivepotentoralflt3inhibitorinpatinetswithflt3mutatedrelapsedorrefractoryacutemyeloidleukemia AT yli p591preliminaryresultsofaphaseistudyofclifutinibahighlyselectivepotentoralflt3inhibitorinpatinetswithflt3mutatedrelapsedorrefractoryacutemyeloidleukemia AT tchen p591preliminaryresultsofaphaseistudyofclifutinibahighlyselectivepotentoralflt3inhibitorinpatinetswithflt3mutatedrelapsedorrefractoryacutemyeloidleukemia AT xfeng p591preliminaryresultsofaphaseistudyofclifutinibahighlyselectivepotentoralflt3inhibitorinpatinetswithflt3mutatedrelapsedorrefractoryacutemyeloidleukemia AT jzhou p591preliminaryresultsofaphaseistudyofclifutinibahighlyselectivepotentoralflt3inhibitorinpatinetswithflt3mutatedrelapsedorrefractoryacutemyeloidleukemia AT mhou p591preliminaryresultsofaphaseistudyofclifutinibahighlyselectivepotentoralflt3inhibitorinpatinetswithflt3mutatedrelapsedorrefractoryacutemyeloidleukemia AT rfu p591preliminaryresultsofaphaseistudyofclifutinibahighlyselectivepotentoralflt3inhibitorinpatinetswithflt3mutatedrelapsedorrefractoryacutemyeloidleukemia AT jlan p591preliminaryresultsofaphaseistudyofclifutinibahighlyselectivepotentoralflt3inhibitorinpatinetswithflt3mutatedrelapsedorrefractoryacutemyeloidleukemia AT xhu p591preliminaryresultsofaphaseistudyofclifutinibahighlyselectivepotentoralflt3inhibitorinpatinetswithflt3mutatedrelapsedorrefractoryacutemyeloidleukemia AT shuang p591preliminaryresultsofaphaseistudyofclifutinibahighlyselectivepotentoralflt3inhibitorinpatinetswithflt3mutatedrelapsedorrefractoryacutemyeloidleukemia AT jwang p591preliminaryresultsofaphaseistudyofclifutinibahighlyselectivepotentoralflt3inhibitorinpatinetswithflt3mutatedrelapsedorrefractoryacutemyeloidleukemia AT xdu p591preliminaryresultsofaphaseistudyofclifutinibahighlyselectivepotentoralflt3inhibitorinpatinetswithflt3mutatedrelapsedorrefractoryacutemyeloidleukemia AT hyang p591preliminaryresultsofaphaseistudyofclifutinibahighlyselectivepotentoralflt3inhibitorinpatinetswithflt3mutatedrelapsedorrefractoryacutemyeloidleukemia AT hyang p591preliminaryresultsofaphaseistudyofclifutinibahighlyselectivepotentoralflt3inhibitorinpatinetswithflt3mutatedrelapsedorrefractoryacutemyeloidleukemia AT hwang p591preliminaryresultsofaphaseistudyofclifutinibahighlyselectivepotentoralflt3inhibitorinpatinetswithflt3mutatedrelapsedorrefractoryacutemyeloidleukemia AT lzheng p591preliminaryresultsofaphaseistudyofclifutinibahighlyselectivepotentoralflt3inhibitorinpatinetswithflt3mutatedrelapsedorrefractoryacutemyeloidleukemia AT zwang p591preliminaryresultsofaphaseistudyofclifutinibahighlyselectivepotentoralflt3inhibitorinpatinetswithflt3mutatedrelapsedorrefractoryacutemyeloidleukemia AT bliu p591preliminaryresultsofaphaseistudyofclifutinibahighlyselectivepotentoralflt3inhibitorinpatinetswithflt3mutatedrelapsedorrefractoryacutemyeloidleukemia AT nkang p591preliminaryresultsofaphaseistudyofclifutinibahighlyselectivepotentoralflt3inhibitorinpatinetswithflt3mutatedrelapsedorrefractoryacutemyeloidleukemia AT yzhuang p591preliminaryresultsofaphaseistudyofclifutinibahighlyselectivepotentoralflt3inhibitorinpatinetswithflt3mutatedrelapsedorrefractoryacutemyeloidleukemia AT yzhang p591preliminaryresultsofaphaseistudyofclifutinibahighlyselectivepotentoralflt3inhibitorinpatinetswithflt3mutatedrelapsedorrefractoryacutemyeloidleukemia AT jjin p591preliminaryresultsofaphaseistudyofclifutinibahighlyselectivepotentoralflt3inhibitorinpatinetswithflt3mutatedrelapsedorrefractoryacutemyeloidleukemia |